The best and worst celebrity pharma moments

We present to you our picks for the best and worst moments in celebrity healthcare spokespersonship—plus a few more that, frankly, we can't find anywhere.

Celebrity drug ads: Opportunity or PR disaster?

Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.

Toenail fungus, IBS drugs headline pharma Super Bowl play

It's the industry's biggest turnout in the Super Bowl in three years.

Five things for pharma marketers to know: Tuesday, February 9, 2016

Five things for pharma marketers to know: Tuesday, February 9, 2016

The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto

Startup unveils tools to improve trial reproducibility

Startup unveils tools to improve trial reproducibility

The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.

New consumer concerns harder for health brands to swallow

New consumer concerns harder for health brands to swallow

Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.

50 celebrity healthcare endorsements

50 celebrity healthcare endorsements

Here's Jon Bon Jovi for Advil, Arnold Palmer for Xarelto and 48 more past and present celebrity endorsements of drugs, healthcare products and disease awareness campaigns.

Five things for pharma marketers to know: Monday, February 8, 2016

Five things for pharma marketers to know: Monday, February 8, 2016

PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team

Taking a Tinder Approach to the Agency-Client Relationship

Taking a Tinder Approach to the Agency-Client Relationship

Imagine if you could choose your agency partners based on attributes most appealing to you. With a swipe to the right or left, you could secure them a roster position or doom them to languish in procurement.

15 unexpected Twitter responses to the "Who Pneu?" campaign

15 unexpected Twitter responses to the "Who Pneu?" campaign

Celebrity success or fail? Here's what the American Lung Association, Pfizer and Tim Daly likely did not see coming when they joined forces to raise awareness about pneumococcal pneumonia.

Five things for pharma marketers to know: Friday, February 5, 2016

Five things for pharma marketers to know: Friday, February 5, 2016

Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

Ascension Health ups Ragone to chief marcomms officer

Ascension Health ups Ragone to chief marcomms officer

The Ketchum veteran joined the nonprofit healthcare system in mid-2014.

House Oversight committee upbraids Turing, Valeant execs

House Oversight committee upbraids Turing, Valeant execs

A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.

Five things for pharma marketers to know: Thursday, February 4, 2016

Five things for pharma marketers to know: Thursday, February 4, 2016

Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet

4 Industry Execs Examine the State of Physician-Rep Access

4 Industry Execs Examine the State of Physician-Rep Access

Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?

McCann Torre Lazur names new president

McCann Torre Lazur names new president

After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.

Agency Spotlight


Email Newsletters